Arax Advisory Partners’s ImmunityBio IBRX Stock Holding History

Arax Advisory Partners’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$243K	Buy	27,788 +25,933	+1,398%	+$196K	﹤0.01%	2110
2026 Q1	$14.2K	Sell	1,855 -20,301	-92%	-$139K	﹤0.01%	2265
2025 Q4	$43.9K	Buy	22,156 +5,925	+37%	+$13.4K	﹤0.01%	1676
2025 Q3	$39.9K	Buy	16,231 +15,631	+2,605%	+$40.3K	﹤0.01%	1936
2025 Q2	$1.58K	Hold	600	–	–	﹤0.01%	2643
2025 Q1	$1.81K	Hold	600	–	–	﹤0.01%	2100
2024 Q4	$1.54K	Sell	600 -8	-1%	-$33	﹤0.01%	2070
2024 Q3	$2.26K	Sell	608 -236	-28%	-$1.09K	﹤0.01%	2025
2024 Q2	$5.33K	Buy	844 +244	+41%	+$1.61K	﹤0.01%	1569
2024 Q1	$3.22K	Hold	600	–	–	﹤0.01%	974
2023 Q4	$3.01K	Hold	600	–	–	﹤0.01%	967
2023 Q3	$1.01K	Hold	600	–	–	﹤0.01%	1122
2023 Q2	$1.67K	Hold	600	–	–	﹤0.01%	1030
2023 Q1	$1.09K	Hold	600	–	–	﹤0.01%	1088
2022 Q4	$3.04K	Hold	600	–	–	﹤0.01%	895
2022 Q3	$3K	Hold	600	–	–	﹤0.01%	907
2022 Q2	$2K	Hold	600	–	–	﹤0.01%	949
2022 Q1	$3K	Hold	600	–	–	﹤0.01%	883
2021 Q4	$4K	Hold	600	–	–	﹤0.01%	804
2021 Q3	$6K	Buy	+600	New	+$6.6K	﹤0.01%	732

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arax Advisory Partners's IBRX Position: Q2 2026 in Review

Arax Advisory Partners increased its ImmunityBio (IBRX) stake by 1,398% in Q2 2026, buying an estimated $196K and bringing the position to 27,788 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #2110.

Arax Advisory Partners first reported a position in IBRX in Q3 2021 and has held it in 20 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Arax Advisory Partners held 27,788 shares of ImmunityBio worth $243K as of Q2 2026.
Arax Advisory Partners bought 25,933 ImmunityBio shares in Q2 2026, an estimated $196K.
ImmunityBio made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2110 holding.
Arax Advisory Partners first reported a position in ImmunityBio in Q3 2021 and has held it in 20 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.